目的 观察选择性5-羟色胺再摄取抑制剂艾司西肽普兰对血小板功能的影响。方法 选取抑郁症患者61例,随机分为治疗组（艾司西酞普兰10 mg/日）和安慰剂对照组,测定治疗前后的血小板计数（PLT）、血小板平均体积（MPV）、血小板分布宽度（...目的 观察选择性5-羟色胺再摄取抑制剂艾司西肽普兰对血小板功能的影响。方法 选取抑郁症患者61例,随机分为治疗组（艾司西酞普兰10 mg/日）和安慰剂对照组,测定治疗前后的血小板计数（PLT）、血小板平均体积（MPV）、血小板分布宽度（PDW）、血小板聚集率（PAR）、血小板膜糖蛋白CD62P和CD63表达。结果 治疗组在治疗前后的PLT（109/L）,MPV（fl）,PDW（fl）,PAR（%）,CD62P（%）和CD63（%）分别为175.8±59.1 vs 169.1±60.5,11.8±1.2 vs 10.3±0.9,15.6±2.1 vs 16.7±1.9,60.1±11.5 vs 59.3±14.9,23.8±5.6 vs25.1±3.7,20.6±7.2 vs 22.4±4.7,对照组在治疗前后的PLT（109/L）,MPV（fl）,PDW（fl）,PAR（%）,CD62P（%）和CD63（%）分别为198.6±76.5 vs 203.2±49.8,9.4±1.1 vs 10.2±0.8,12.5±1.8 vs 13.3±2.9,62.7±13.6 vs 66.4±10.7,27.9±7.1 vs 24.8±4.9,26.9±8.1 vs 24.1±6.4,差异均无统计学意义（均P〉0.05）。结论 艾司西肽普兰对血小板功能无明显影响。展开更多
Introduction:Selective serotonin reuptake inhibitors(SSRIs) are frequently used in the treatment of irritable bowel syndrome(IBS) although evidence of their efficacy is scarce.Aim:Twenty three non-depressed IBS patien...Introduction:Selective serotonin reuptake inhibitors(SSRIs) are frequently used in the treatment of irritable bowel syndrome(IBS) although evidence of their efficacy is scarce.Aim:Twenty three non-depressed IBS patients were recruited from a tertiary care centre and included in a crossover trial comparing six weeks of treatment with the SSRI citalopram(20 mg for three weeks,40 mg for three weeks) with placebo.IBS symptom severity was the primary outcome measure,and depression and anxiety scores were also measured.The effect of acute administration of citalopram on colonic sensitivity and on colonic response to feeding was investigated as a putative predictor of symptomatic response to the drug.Results:After three and six weeks of treatment,citalopram significantly improved abdominal pain,bloating,impact of symptoms on daily life,and overall well being compared with placebo.There was only a modest effect on stool pattern.Changes in depression or anxiety scores were not related to symptom improvement.The effect of acute administration of citalopram during a colonic barostat study did not predict clinical outcome.Analysis of the first treatment period as a double blind parallel arm study confirmed the benefit of citalopram over placebo.Conclusions:The SSRI citalopram significantly improves IBS symptoms,including abdominal pain,compared with placebo.The therapeutic effect is independent of effects on anxiety,depression,and colonic sensorimotor function.展开更多
文摘目的 观察选择性5-羟色胺再摄取抑制剂艾司西肽普兰对血小板功能的影响。方法 选取抑郁症患者61例,随机分为治疗组（艾司西酞普兰10 mg/日）和安慰剂对照组,测定治疗前后的血小板计数（PLT）、血小板平均体积（MPV）、血小板分布宽度（PDW）、血小板聚集率（PAR）、血小板膜糖蛋白CD62P和CD63表达。结果 治疗组在治疗前后的PLT（109/L）,MPV（fl）,PDW（fl）,PAR（%）,CD62P（%）和CD63（%）分别为175.8±59.1 vs 169.1±60.5,11.8±1.2 vs 10.3±0.9,15.6±2.1 vs 16.7±1.9,60.1±11.5 vs 59.3±14.9,23.8±5.6 vs25.1±3.7,20.6±7.2 vs 22.4±4.7,对照组在治疗前后的PLT（109/L）,MPV（fl）,PDW（fl）,PAR（%）,CD62P（%）和CD63（%）分别为198.6±76.5 vs 203.2±49.8,9.4±1.1 vs 10.2±0.8,12.5±1.8 vs 13.3±2.9,62.7±13.6 vs 66.4±10.7,27.9±7.1 vs 24.8±4.9,26.9±8.1 vs 24.1±6.4,差异均无统计学意义（均P〉0.05）。结论 艾司西肽普兰对血小板功能无明显影响。
文摘Introduction:Selective serotonin reuptake inhibitors(SSRIs) are frequently used in the treatment of irritable bowel syndrome(IBS) although evidence of their efficacy is scarce.Aim:Twenty three non-depressed IBS patients were recruited from a tertiary care centre and included in a crossover trial comparing six weeks of treatment with the SSRI citalopram(20 mg for three weeks,40 mg for three weeks) with placebo.IBS symptom severity was the primary outcome measure,and depression and anxiety scores were also measured.The effect of acute administration of citalopram on colonic sensitivity and on colonic response to feeding was investigated as a putative predictor of symptomatic response to the drug.Results:After three and six weeks of treatment,citalopram significantly improved abdominal pain,bloating,impact of symptoms on daily life,and overall well being compared with placebo.There was only a modest effect on stool pattern.Changes in depression or anxiety scores were not related to symptom improvement.The effect of acute administration of citalopram during a colonic barostat study did not predict clinical outcome.Analysis of the first treatment period as a double blind parallel arm study confirmed the benefit of citalopram over placebo.Conclusions:The SSRI citalopram significantly improves IBS symptoms,including abdominal pain,compared with placebo.The therapeutic effect is independent of effects on anxiety,depression,and colonic sensorimotor function.
